Xoma files against Biosite Diagnostics:
This article was originally published in Clinica
Biopharmaceutical company Xoma has filed a complaint against Biosite Diagnostics alleging infringement of its bacterial cell expression technology patents in connection with some of Biosite's technologies and collaborations. Berkeley, California-based Xoma is seeking an injunction and damages for fraud and misrepresentation, breach of contract, misappropriation and unfair business practices. It has also filed a motion to dismiss a declaratory judgement action filed by Biosite.
You may also be interested in...
BD and BioMedomics have released a new rapid point-of-care test that can detect antibodies in blood to confirm current or past exposure to COVID-19.
A medtech industry group is asking the Trump administration to clarify if small medical device companies that have equity investors qualify for small business loans and forgiveness under the coronavirus relief package.
Amarin had argued that Vascepa’s sales success showed that its patents were not obvious, but the court found otherwise, even as it concluded that Hikma, Dr. Reddy's and West-Ward has infringed on the fish oil pill's patents.